Personalizing Treatment Options Across the Continuum of MDS and sAML

The number of approved drugs for myelodysplastic syndromes (MDS) is limited, and not all agents have been shown to be highly efficacious and to improve survival. However, the oncology community witnessed an explosion of new agents and investigational approaches in 2020 that has persisted until today.

In this virtual symposium hear expert insights regarding the role of cytogenetic abnormalities, new prognostic models, and other patient- and disease-related factors in diagnosis, prognosis, and treatment planning for individuals with MDS. Faculty will also assess the clinical implications of recent and emerging safety and efficacy data for novel agents and combinations and provide strategies for effective communication with patients, including those in special populations and those of diverse backgrounds, to manage symptoms and enhance quality of life.

This virtual Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.